Beraprost modified release - Astellas Pharma/Kaken Pharmaceuticals/Toray Industries

Drug Profile

Beraprost modified release - Astellas Pharma/Kaken Pharmaceuticals/Toray Industries

Alternative Names: Beraprost controlled release; Beraprost MR - Astellas Pharma/Kaken Pharmaceuticals/Toray Industries; Beraprost sustained release; Beraprost-SR; Berasus; Careload LA; TRK-100STP; YM 533

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Toray
  • Developer Astellas Pharma; Kaken Pharmaceutical; Toray
  • Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Discontinued Renal failure; Spinal stenosis

Most Recent Events

  • 01 Aug 2014 Toray and Astellas complete a phase II/III trial in Renal failure in China, Hong Kong, Japan, Malaysia, South Korea, Taiwan and Thailand (NCT01090037)
  • 01 Feb 2014 Toray Industries completes a phase I trial in Renal impairment in Japan (NCT01443429)
  • 01 May 2008 Toray completes enrolment in its phase II trial for Renal failure in Japan (NCT02480751)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top